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A B S T R A C T
Purpose: To evaluate sleep disturbances or sleep related events and their characteristics among patients
with medically refractory epilepsy, compared to those with controlled epilepsy.
Methods: In a prospective case-controlled study, patients of medically refractory and controlled epilepsy
were recruited and history pertaining to epilepsy and sleep related events and Epworth sleepiness scores
were recorded and all patients underwent over night polysomnography.
Results: Among 40 patients, 20 with medically refractory (Group 1) and 20 with controlled epilepsy
(Group 2) (median age 18, range 10–35 years), the self reported sleep parameters in Group 1 patients
were found to be signiﬁcantly different as compared to Group 2, in terms of the duration of night time
sleep, day time sleep, day time nap frequency, total sleep hours per day, excessive daytime sleepiness
(EDS)(45% vs. 15%) and average sleep hours over the week prior to polysomnography. On PSG, Group 1
patients showed signiﬁcantly less total sleep time [340.4 min (147–673) vs. 450.3 min (330–570)] with
delayed sleep latency and REM latency, poor sleep efﬁciency [80.45 (40.5–98.0) vs. 95.45 (88.4–99.7)]
and frequent arousals and wake after sleep onset (WASO) compared to Group 2 patients. Four patients
(20%) in Group 1 compared to none in Group 2 were found to have mild obstructive sleep apnea.
Conclusions: Our results indicate that medically refractory epilepsy patients believe that they spend
more time sleeping, in contrast to the documented shorter sleep duration on polysomnography. This
difference between perceived and actual sleep seems, by their data, to arise mainly from sleep
fragmentation, disturbed architecture and the interesting ﬁnding of associated sleep apnea among the
medically refractory epilepsy patients.
 2012 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
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Epilepsy and sleep disorders are both major health problems
across the globe and simultaneous occurrence of sleep disorders
and epilepsy is not uncommon.1 Various studies have showed high
prevalence of sleep disturbances [including obstructive sleep
apnea syndrome (OSAS), excessive daytime sleepiness (EDS),
hypersomnia, narcolepsy, periodic limb movement disorder
(PLMD) and restless leg syndrome (RLS)] in epilepsy patients
compared to general population, and sleep disturbance in patients
with epilepsy is even independent of drug treatment and may be
inherent to the disorder itself.2–6 The etiology for sleep dis-
turbances in epilepsy seems to be multi-factorial and includes
abnormal architecture of sleep due to epilepsy, effects of
antiepileptic drugs (AEDs), detrimental effects of seizures on* Corresponding author at: R.No. 2, 6th Floor, Neurosciences Center, All India
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http://dx.doi.org/10.1016/j.seizure.2012.04.005sleep, in addition to insufﬁcient sleep time, poor sleep hygiene and
coexistence of primary sleep disorders or co-morbid illness.7
Considering these effects of seizures and epilepsy, as a disorder,
in general, on sleep, it is possible that sleep related events are more
prevalent in medically refractory epilepsy as compared to
medically controlled epilepsy. Direct comparison of sleep related
events among patients with medically refractory and controlled
epilepsy is not reported in literature. We hypothesize that sleep
related events and sleep disturbances would be observed more
often in medically refractory epilepsy compared to controlled
epilepsy. The aim of the study is to evaluate sleep disturbances or
sleep related events and their characteristics in medically
refractory epilepsy compared to controlled epilepsy.
2. Materials and methods
2.1. Subjects and controls
This is a prospective cohort study, conducted at the Department
of Neurology, All India Institute of Medical Sciences (AIIMS), Newvier Ltd. All rights reserved.
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medically refractory epilepsy (Group 1) and medically controlled
epilepsy (Group 2) attending our Epilepsy Clinic. Patients included
in Group 1 were those with seizures persisting at a frequency of >1
per month for at least 6 months prior to assessment, on optimum
doses of >2 AEDs with good compliance; and those included in
Group 2 had history of seizures controlled on one or two AEDs for
the past 6 months. Exclusion criteria were co-morbid neurological
illness which can affect sleep, like stroke, encephalitis/meningitis,
metabolic encephalopathy and others; coexisting medical illnesses
like hypothyroidism and chronic respiratory diseases or known
primary sleep disorders like obstructive sleep apnea (OSA) or
narcolepsy in absence of epilepsy disorder. This study was
approved by the Institutional Ethics Committee of AIIMS.
2.2. Sample size and selection of controls
Since there is no single published study, which has compared
clinical and polysomnographic parameters between medically
refractory epilepsy and controlled epilepsy cohorts, we intended to
recruit patients based on the ‘purposeful sampling method’ with
1:1 age and sex matched controls depending on the availability of
polysomnography appointments for research purpose during the
period of study.
2.3. Characteristics of subjects and controls
Following an informed consent, a detailed history, including
age, sex, age of onset, duration of epilepsy; frequency and
semiology of seizures; and drugs (AEDs, others) history was taken
through a pre-structured questionnaire. Sleep history was
collected through another pre-structured questionnaire to speciﬁ-
cally question for features of sleep disordered breathing, RLS,
PLMD, narcolepsy, insomnia and circadian rhythm sleep disorders.
Details about usual sleep habits were also asked for. Epworth
sleepiness scale (ESS) was scored for all patients, and they were all
required to ﬁll a 1-week sleep log immediately preceding the
polysomnography (PSG) study. The clinical examination of all
patients was performed in detail.
2.4. Sleep study, sleep parameters, and polysomnographic diagnosis
PSG studies were performed with the simultaneous use of a
pressure transducer and thermistor for nasal ﬂow, piezoelectric
chest and abdominal belts, and end-tidal CO2 monitoring, as well
as pulse oximetry, a snore microphone, two leg channels, a chin
electromyogram, extended electroencephalogram montage, an
electrocardiogram, and simultaneous video monitoring.8 Deﬁni-
tion of all PSG parameters as well as speciﬁc diagnosis e.g., OSA,
PMLD, was based on American Academy of Sleep Medicine (AASM)
guidelines.9
2.5. Outcome measures
The following sleep parameters were assessed on PSG: total
sleep time (TST), sleep latency, REM latency, sleep efﬁciency,
awakening, arousals, arousal index (AI), apnea-hypopnea index
(AHI), total periodic leg movements, periodic limb movement
index (PLMI), and desaturation index (DI).
2.6. Statistical analysis
The statistical analysis was carried out by using SPSS version
15.0 and EpiInfo version 6.4. The data was represented as
mean  SD (standard deviation) as well as median (with range).
The comparison between two groups for continuous variables, wasdone by applying Student’s t test or Mann–Whitney test, wherever
applicable. The qualitative data were compared by applying chi-
square or Fisher’s exact test. Log transformation was also applied to
skewed variables. p-Value less than 0.05 was considered as
signiﬁcant.
3. Results
3.1. Baseline characteristics
In this study, we recruited consecutive 40 patients, 20 each of
medically refractory epilepsy (Group 1) and medically controlled
epilepsy (Group 2) attending our Epilepsy Clinic. At baseline, both
the groups had similar clinical and demographic features (Table 1) in
terms of age and gender. The age of onset of seizures, duration and
frequency of seizures, and number and duration of AEDs were
signiﬁcantly higher in Group 1. The commonest seizure type was
focal dyscognitive seizure with secondary generalization (70%) in
Group 1, compared to simple focal motor seizures (45%) in Group 2.
Apart from 2 patients in Group 1, none of the other patients in either
group had seizures during the week prior to and on the night of the
PSG recording. In Group 1, the number of patients taking clobazam
and levetiractam was signiﬁcantly higher than Group 2 with p value
of 0.01. The frequency of abnormal imaging was signiﬁcantly higher
in Group 1, which mainly constituted mesial temporal sclerosis, and
frontal or parietal cortical dysplasia, and peri-natal insult with peri-
ventricular white matter hyper-intensity.
3.2. Clinical sleep parameters
On evaluation of the clinical aspect of sleep, we found that
among patients in Group 1, the duration of night time sleep, day
time sleep, day time nap frequency, total sleep hours per day, ESS
scores and average sleep hours in last week before PSG were
signiﬁcantly higher as compared to Group 2 (Table 2). Although
ESS scores were signiﬁcantly higher in Group 1, the number of
patients with ESS >10 (representing clinically signiﬁcant EDS), was
found to be similar in both the groups.
3.3. Polysomnographic parameters
An interesting PSG ﬁnding in this study is that the average of
total sleep time is in fact shorter among patients in Group 1, in
contrast to self-reported average sleep time per 24 h (Table 3). The
sleep efﬁciency, arousals and AI were signiﬁcantly more abnormal
and there were signiﬁcantly more frequent awakenings in this
group of patients. Respiratory events were observed more
frequently in Group 1, although not reaching statistical signiﬁ-
cance. Higher arousal indices in Group 1 were independent of
seizure occurrences (not observed in any patient during PSG
recording), and mostly spontaneous except in 2 patients with OSA,
who had respiratory disturbance associated arousals. A signiﬁ-
cantly higher number of patients (4/20) in Group 1 were found to
have an AHI >5, which denotes mild OSA; as compared to none in
Group 2 (p = 0.01). Signiﬁcantly more frequent desaturations were
also observed in Group 1. Patients in Group 2 had signiﬁcantly
higher numbers of limb movements; however, PLMI was
comparable in both the groups.
4. Discussion
In the present study we sought to characterize abnormalities in
sleep architecture and quality, as well as distribution of primary
sleep disorders, if any, in a cohort of patients with medically
refractory vs. controlled epilepsy. Self reported total sleep time per
24 h was signiﬁcantly longer in patients with refractory epilepsy,
Table 1
Demographic and clinical details of patients with epilepsy undergoing PSG evaluation.
Variables Intractable epilepsy group Controlled epilepsy group p-Value
(Group 1) (n = 20) (Group 2) (n = 20)
Age (median) 18 (10–35) 18.5 (11–35) 0.43
Sex – male:female 13:7 15:5 0.49
Age of onset, duration and frequency of seizures (median and range)
Age of onset of seizures (years) 4.75 (0–32) 15.0 (1–30) 0.01
Duration of Seizures (years) 12.5 (0.1–34) 3 (0.5–34) 0.01
Frequency (per month) 52.5 (4–8500) 0.75 (0.3–2) 0.01
Type of seizures (number and percentage)
Simple focal motor 0 (0%) 9 (45%) <0.01
Focal dyscognitive 6 (30%) 1 (5%) 0.09
Focal dyscognitive with secondary generalization 14 (70%) 4 (20%) 0.001
Generalized 0 (0%) 6 (30%) 0.02
Time of seizures (number and percentage)
Day 8 (40%) 8 (40%)
Night 0 (0%) 2 (10%) 0.34
Day/night 12 (60%) 10 (50%)
AEDs (number, percentage or median and range)
Number of AEDs 3 (2–6) 1 (1–2) 0.01
Duration of AEDs (years) 12 (0.1–33) 2 (0.5–5) 0.01
Duration of last change of AEDs (years) 0.4 (0–3.0) 2. 0 (0.5–4) 0.01
DPH 3 (15%) 3 (15%) 1.0
VLP 10 (50%) 9 (45%) 0.75
CBZ 6 (30%) 4 (20%) 0.46
OxCBZ 8 (42.2%) 4 (20%) 0.14
PBT 2 (10%) 1 (5%) 1.0
LEV 15 (75%) 1 (5%) 0.01
LMT 1 (5%) 1 (5%) 1.0
CLB 12 (60%) 5 (25%) 0.02
ZNS 3 (15%) 0 (0%) 0.23
TPM 3 (15.8%) 0 (0%) 0.11
Imaging (number and percentage)
Abnormal imaging 20 (100%) 8 (40%) 0.01
Abbreviations: AEDs – antiepileptic drugs; DPH – diphenhydratoin; VLP – sodium valproate; CBZ – carbamazepine; OxCBZ – oxcarbamazepine; PBT – phenobarbitone; LEV –
levetiracetam; LMT – lamotrigine; CLB – clobazam, ZNS – zonisamide; TPM – topiramate.
Table 2
Self reported clinical sleep parameters among the patients with epilepsy.
Variables Intractable epilepsy group Controlled epilepsy group p-Value
Percentage, median (range) (Group 1) (n = 20) (Group 2) (n = 20)
Sleep duration in night 9.0 (7.0–11.0) 8.0 (6.0–10.0) 0.01
Sleep duration in daytime 2.0 (0–5) 0.0 (0–3) 0.03
Total sleep time per 24 h 10.5 (8.0–15.0) 9.0 (7.0–11.0) 0.04
Day time nap 15 (75%) 8 (40%) 0.03
EDS 9 (45%) 3 (15%) 0.04
ESS >10 6 (30%) 2 (10%) 0.24
Previous week average sleep time (h) 10.0 (8.0–13.0) 8.75 (7.0–10.0) <0.01
Abbreviations: EDS – excessive daytime sleepiness; ESS – Epworth sleepiness scale.
Table 3
Polysomnographic parameters observed in patients with epilepsy.
Variables Intractable epilepsy group Controlled epilepsy group p-Value
[% or median (range)] (Group 1) (n = 20) (Group 2) (n = 20)
Sleep related events
Total sleep time (min) 340.4 (147–673) 450.3 (330–570) 0.01
Sleep latency (min) 14 (4.0–112.5) 6 (1.0–55.3) 0.01
REM latency (min) 126 (31–368) 114 (60–360) 0.14
Sleep efﬁciency (%) 80.5 (40.5–98.0) 95. 5 (88.4–99.7) 0.01
WASO (%) 19.5 (1–56) 4.0 (1–14) 0.01
Arousals 53.5 (0–167) 37 (11–108) 0.05
Arousal index 10.0 (0–31.4) 5.2 (0–15.8) 0.01
AHI 1.22 (0–11.93) 0.88 (0–2.36) 0.10
AHI  5 (number, %) 4 (20%) 0 (0) 0.01
DI 0.7 (0–7.6) 0.25 (0–2.0) 0.05
LMs 2.0 (0–13) 6.0 (0–23) 0.04
PMLI 0.3 (0–2.4) 0.8 (0–2.8) 0.12
Abbreviations: WASO – wakefulness after sleep onset; AHI – apnea hypopnea index; DI – desaturation index; LMs – limb movements; PLMI – periodic limb movement index.
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of sleep was markedly disturbed, the efﬁciency of sleep was poorer,
and there were more frequent arousals and awakenings among the
patients with medically refractory epilepsy. The prevalence of mild
OSA was signiﬁcantly higher in the medically refractory epilepsy
group.
Published literature on detailed comparison of patients with
refractory epilepsy and those controlled on AEDs, is sparse.
Kaleyias et al.10 in 2008, in 40 pediatric age group patients,
reported that intractable epilepsy patients have longer sleep
latency [43.5 (17–86.5) vs. 19.5 (11–71)], poor sleep efﬁciency [74
(70–82) vs. 83 (74–92)] along with higher arousal index [35 (22–
40) vs. 20 (13–23)] as compared to medically controlled epilepsy.
Our ﬁndings regarding total sleep time, sleep efﬁciency, REM
latency, AHI, DI and AI are similar to those in the quoted study. The
only major difference observed by us is the much shorter sleep
latencies among our patients in both groups, while the inter-group
differences noted were similar.
The interesting ﬁnding in our study was that signiﬁcantly less
number of Group 1 patients had LMs as compared to Group 2
patients. This ﬁnding is unlikely to be clinically signiﬁcant as the
index in both groups is quite low. The difference could, however, be
attributed to AEDs, speciﬁcally carbamazepine and valproic acid,
which might decrease PLMs.11
OSA was more frequently observed in Group 1 compared to
Group 2 (20% vs. none) (mean (range) AHI 1.22 (0–11.9)/h in Group
1 vs. 0.88 (0–2.36)/h in Group 2), in our study. This ﬁnding of
increased sleep apnea in the refractory group is conﬁrmatory to
previous work. In a study by Malow et al., the prevalence of OSA
was 30% in intractable epilepsy group and 10% of unselected adult
epilepsy group.3 The reason for low prevalence in our study may be
the younger age group of our subjects. However, more reasons
need to be explored in future.
Our study demonstrates that medical refractoriness in patients
with epilepsy has a deleterious effect on sleep quality in general.
Although, this speciﬁc aspect of epilepsy and sleep relationship has
not been discussed except in the study by Kaleyias et al.,10 sleep
disturbances may have a major impact on quality of life in patients
with refractory epilepsy. Hence, treatment strategies speciﬁcally
targeting refractory patients, e.g. epilepsy surgery, ketogenic diet,
or vagal nerve stimulation may bear the potential to improve sleep
quality and contribute to overall improvement in quality of life.
Interestingly, we did not record any seizures during any of the
PSG recordings or a day before PSG, even in patients with high
frequency seizures. However, this is a valuable coincidence, since,
non-occurrence of seizures in both groups rules out the possibility
of disturbed sleep being attributed to clinical phenomena
disrupting sleep on the night of the PSG recording. One of the
limitations of this study was that electroencephalogram (EEG)
recorded was not a full 16 channel EEG; hence, commenting on
epileptic phenomena on EEG also might be difﬁcult.
Other limitations of our study include the relatively small
sample size and the large number of variables studied. More
studies focusing on individual clinical and polysomnographicaspects of sleep among larger number of patients in speciﬁc
subsets of medically refractory epilepsy patients are needed to be
conducted, in future, to see if these results can be generalized to all
patients with medically refractory epilepsy.
Another limitation in our cohort is that, patients in Group 1
were taking statistically signiﬁcantly more number of AEDs
(especially, levetiracetam and clobazam) for longer duration.
However, levetiracetam does not have major effects on sleep
structure,12 while clobazam is expected to reduce sleep stages 3, 4
and REM and to improve sleep consolidation,13 which was not
documented in our study.
5. Conclusion
Our results indicate that medically refractory epilepsy patients
believe they spend more time in sleeping, in contrast to
documented lesser sleep duration on PSG. This difference between
perceived and actual sleep seems, by their data, to arise mainly
from sleep fragmentation, disturbed architecture and interesting
ﬁnding of associated sleep apnea in medically refractory epilepsy
patients.
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